The author discusses the sustainability of international reference pricing (IRP) and price negotiations for innovative new drugs. He notes that IRP or price negotiations are not sustainable in the absence of agreement and predicts to result in value-based pricing (VBP). He points out that countries where IRP is followed by price negotiations may employ criteria in addition to reference prices.